Clinical Trials Logo
  1. Home
  2. Endometrium Cancer
  3. NCT04603599
  4. Details
NCT04603599 Clinical Trial

Relationship of Endometrial Cancer and Serum Soluble L1CAM Level

Endometrium Cancer Clinical Trial

Official title:
Relationship of Endometrial Cancer and Serum Soluble L1CAM Level

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04603599
Other study ID # Merve L1CAM
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2019
Est. completion date December 31, 2019

Study information
Verified date October 2020
Source Kocaeli University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to evaluate the effect of serum soluble L1CAM (sL1CAM) on the diagnosis and prognosis of endometrial cancer. This prospective randomized controlled trial will be conducted in patients who have undergone endometrial biopsy and whose pathology results are reported as benign endometrial changes, endometrial hyperplasia, or endometrial cancer. The sL1CAM level between groups will be compared. The relationship between prognostic factors and serum sL1CAM will be evaluated in patients with endometrial cancer.

Recruitment information / eligibility
Status Completed
Enrollment 146
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who underwent endometrial biopsy due to abnormal uterine bleeding and whose pathology results were reported as benign endometrial changes, endometrial hyperplasia or endometrial cancer were included in the study. All patients participating in the study signed informed consent. Exclusion Criteria: - Patients who did not have consent, received neoadjuvant therapy and who would not have surgery despite endometrial cancer were excluded from the study.

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• serum soluble L1CAM (sL1CAM)
blood sample

Locations
Country Name City State
Turkey Merve Demir Kocaeli

Sponsors (1)
Lead Sponsor Collaborator
Kocaeli University

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary serum sL1CAM level one year
See also
  Status Clinical Trial Phase
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT05902988 - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Phase 1/Phase 2
Recruiting NCT06192017 - Development of a Molecular Diagnostic Tool for Endometrial Cancer.
Completed NCT03899441 - Multimedia Aid Gynecologic Counseling and Consent N/A
Completed NCT02552121 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02001623 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02997553 - Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Phase 3
Suspended NCT03095664 - Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors N/A
Active, not recruiting NCT01466777 - Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy N/A
Completed NCT01068483 - Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients Phase 1
Recruiting NCT03896113 - Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma Phase 2
Not yet recruiting NCT03570866 - PET/CT in the Management of Patients With Early Stage Endometrial Cancer
Completed NCT05246462 - The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients N/A
Withdrawn NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Phase 1/Phase 2
Recruiting NCT05651282 - Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer Phase 4
Completed NCT06187558 - Suspension of the Pelvic and Abdominal Organs During Minimally Invasive Surgery
Completed NCT06312917 - Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer N/A
Active, not recruiting NCT03951415 - Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer Phase 2
Recruiting NCT04212910 - Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model